Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Drug shows promise for stopping excessive sweating

NCT ID NCT01855256

First seen Dec 09, 2025 · Last updated Jun 20, 2026 · Updated 23 times

Summary

This Phase 3 trial tested the drug oxybutynin in 62 adults with excessive sweating (hyperhidrosis). Participants took either oxybutynin or a placebo, starting at a low dose and increasing gradually. The study measured how well the drug reduced sweating and improved quality of life, while also tracking side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERHIDROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHG Landerneau

    Landerneau, 29800, France

  • CHG de Morlaix

    Morlaix, France, 29600, France

  • Dermatologist'S Office

    Quimper, 29000, France

  • Hospital, Brest

    Brest, 29609, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Oxybutynin

What this could lead to

If it works, this could provide a non-surgical treatment option for people with excessive sweating.

What could go wrong

This is a small, completed Phase 3 trial. While results are promising, the drug may cause side effects and may not work for everyone.

Conditions

The condition(s) this trial relates to.

Hyperhidrosis hyperhidrosis palmaris ET plantaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.